Table 2 Large-scale iPSC banks under development
From: What is the point of large-scale collections of human induced pluripotent stem cells?
Bank | Location | Ownership | hiPSC lines banked and available | Comment |
|---|---|---|---|---|
Innovative Medicines Initiative (IMI) EU Centralized iPSC Repository | European Union (EU) | Public-private partnership | Broad disease coverage and diverse ethnicities; goal of >10,000 lines combining cells from all IMI projects and other EU and UK collections | Consortium to be announced in 2013. Collaborative arrangements with other international banks. Open access |
New York Stem Cell Foundation | New York | Not for profit | Building a repository of 2,500 hiPSC lines representing the diversity of United States | Open access for global benefit |
California Institute for Regenerative Medicine | San Francisco | Government owned | $32-million effort to collect and store 9,000 cell lines from 3,000 people across 11 disease areas | Most cells to be made by Cellular Dynamics and banked by the Coriell Institute for Medical Research at the Buck Institute for Research on Aging in Novato |
Kyoto University Center for iPS Cell Research & Application | Kyoto, Japan | Government owned | Just starting, but expect to have 75 lines by 2020 | Cells to be research and clinical grade |
Progenicyte | Orlando, FL, USA | Private company | Not started | In 'near future' will bank |
HipSci | UK | Wellcome Trust/Medical Research Council | Initial phase is 700 normal cell lines, 100 diseased | Open access data and cells |
StemBANCC (stem cells for biological assays of novel drugs and predictive toxicology) | EU | Public-private partnership | Lines from up to 500 individuals to study neurological disorders, diabetes drug safety | 35 partners including 10 pharmaceutical companies. Cells will migrate to EU Centralised hiPSC Repository |
NIMH | Rockville, MD, USA | NIH funded | Lines to study a variety of mental health disorders | Will bank and distribute |
